Skip to main content
SpringerLink
Log in

The Role of Systemic Inflammation in COPD

  • Chapter
  • First Online:
Chronic Obstructive Pulmonary Disease

Part of the book series: Respiratory Medicine ((RM))

Abstract

Chronic obstructive pulmonary disease (COPD) is defined as a preventable and treatable disease with significant extrapulmonary effects. Many of the extra-pulmonary effects of COPD are thought to be mediated by systemic inflammation. Local inflammation has always been appreciated as part of the COPD ­disease ­process; however, it is becoming clear that the inflammatory response is also ­systemic. There are multiple theories about the mechanisms driving the systemic inflammation associated with COPD. However, there is no consensus on which theory is correct. The systemic inflammation likely contributes to systemic manifestations of COPD, including cardiovascular disease, lung cancer, weight loss, osteoporosis and diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–55.

    Article  PubMed  Google Scholar 

  2. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.

    Article  PubMed  CAS  Google Scholar 

  3. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond). 2010; 9(7):29.

    Article  CAS  Google Scholar 

  4. Pinto-Plata VM, Livnat G, Girish M, Cabral H, Masdin P, Linacre P, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007;131(1):37–43.

    Article  PubMed  CAS  Google Scholar 

  5. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Int Med. 2008;19(2):104–8.

    Article  CAS  Google Scholar 

  6. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347–60.

    Article  PubMed  CAS  Google Scholar 

  7. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010;11:77.

    Article  PubMed  CAS  Google Scholar 

  8. Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D. COPD phenotype description using principal components analysis. Respir Res. 2009;10:41.

    Article  PubMed  CAS  Google Scholar 

  9. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002;166(9):1218–24.

    Article  PubMed  Google Scholar 

  10. Michel O, Dentener M, Corazza F, Buurman W, Rylander R. Healthy subjects express differences in clinical responses to inhaled lipopolysaccharide that are related with inflammation and with atopy. J Allergy Clin Immunol. 2001;107(5):797–804.

    Article  PubMed  CAS  Google Scholar 

  11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

    Article  PubMed  CAS  Google Scholar 

  12. Dietrich M, Block G, Benowitz NL, Morrow JD, Hudes M, 3rd Jacob P, et al. Vitamin C supplementation decreases oxidative stress biomarker f2-isoprostanes in plasma of nonsmokers exposed to environmental tobacco smoke. Nutr Cancer. 2003;45(2):176–84.

    Article  PubMed  CAS  Google Scholar 

  13. Sabit R, Thomas P, Shale DJ, Collins P, Linnane SJ. The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. Chest. 2010;138(1):47–51.

    PubMed  CAS  Google Scholar 

  14. Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1179–84.

    PubMed  CAS  Google Scholar 

  15. Madjdpour C, Jewell UR, Kneller S, Ziegler U, Schwendener R, Booy C, et al. Decreased alveolar oxygen induces lung inflammation. Am J Physiol Lung Cell Mol Physiol. 2003;284(2): L360–7.

    PubMed  CAS  Google Scholar 

  16. Pini L, Valsecchi A, Boni E, Guerini M, Tantucci C. Acute dynamic hyperinflation and systemic inflammation in stable COPD patients. Am J Respir Crit Care Med. 2010;181:A2907.

    Google Scholar 

  17. Vassilakopoulos T, Katsaounou P, Karatza MH, Kollintza A, Zakynthinos S, Roussos C. Strenuous resistive breathing induces plasma cytokines: role of antioxidants and monocytes. Am J Respir Crit Care Med. 2002;166(12 Pt 1):1572–8.

    Article  PubMed  Google Scholar 

  18. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(6):591–7.

    Article  PubMed  Google Scholar 

  19. Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(7): 573–80.

    Article  PubMed  CAS  Google Scholar 

  20. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173–80.

    Article  PubMed  Google Scholar 

  21. Rabinovich RA, Figueras M, Ardite E, Carbo N, Troosters T, Filella X, et al. Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J. 2003;21(5):789–94.

    Article  PubMed  CAS  Google Scholar 

  22. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernandez N, Talamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J. 2005;26(3):390–7.

    Article  PubMed  CAS  Google Scholar 

  23. Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008;63(2):100–7.

    Article  PubMed  CAS  Google Scholar 

  24. Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF. The effect of cigarette smoking on the bone marrow. Am J Respir Crit Care Med. 1997;155(3):1021–6.

    PubMed  CAS  Google Scholar 

  25. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J. 2003;22(5):809–14.

    Article  PubMed  CAS  Google Scholar 

  26. Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(3):627–43.

    Article  PubMed  CAS  Google Scholar 

  27. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11.

    Article  PubMed  Google Scholar 

  28. Black-Shinn JL, Kinney GL, Wise A, Regan E, Make BJ, Krants M, et al. Cardiovascular disease is associated with COPD severity and reduced functional capacity. Am J Respir Crit Care Med. 2010;181:A5918.

    Google Scholar 

  29. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–9.

    Article  PubMed  CAS  Google Scholar 

  30. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med. 1987;106(4):512–8.

    PubMed  CAS  Google Scholar 

  31. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–9.

    PubMed  Google Scholar 

  32. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007;176(3):285–90.

    Article  PubMed  Google Scholar 

  33. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010; 17(1):89–97.

    Article  PubMed  CAS  Google Scholar 

  34. Dennis PA, Van Waes C, Gutkind JS, Kellar KJ, Vinson C, Mukhin AG, et al. The biology of tobacco and nicotine: bench to bedside. Cancer Epidemiol Biomarkers Prev. 2005;14(4): 764–7.

    Article  PubMed  CAS  Google Scholar 

  35. de Boer WI, Hau CM, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol. 2006;125(2):184–92.

    PubMed  Google Scholar 

  36. Creutzberg EC, Schols AM, Weling-Scheepers CA, Buurman WA, Wouters EF. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(3 Pt 1): 745–52.

    PubMed  CAS  Google Scholar 

  37. Schols AM, Wouters EF. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. Clin Chest Med. 2000;21(4):753–62.

    Article  PubMed  CAS  Google Scholar 

  38. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147(5):1151–6.

    PubMed  CAS  Google Scholar 

  39. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1): 1791–7.

    PubMed  CAS  Google Scholar 

  40. Giron R, Matesanz C, Garcia-Rio F, de Santiago E, Mancha A, Rodriguez-Salvanes F, et al. Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann Nutr Metab. 2009;54(1):52–8.

    Article  PubMed  CAS  Google Scholar 

  41. Baarends EM, Schols AM, Pannemans DL, Westerterp KR, Wouters EF. Total free living energy expenditure in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155(2):549–54.

    PubMed  CAS  Google Scholar 

  42. Schols AM, Fredrix EW, Soeters PB, Westerterp KR, Wouters EF. Resting energy expenditure in patients with chronic obstructive pulmonary disease. Am J Clin Nutr. 1991;54(6): 983–7.

    PubMed  CAS  Google Scholar 

  43. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with COPD: a meta-analysis. Chest. 2000;117(3):672–8.

    Article  PubMed  CAS  Google Scholar 

  44. Gosker HR, Kubat B, Schaart G, van der Vusse GJ, Wouters EF, Schols AM. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;22(2):280–5.

    Article  PubMed  CAS  Google Scholar 

  45. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51(8): 819–24.

    Article  PubMed  CAS  Google Scholar 

  46. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150(5 Pt 1): 1453–5.

    PubMed  Google Scholar 

  47. Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax. 2004;59(6): 483–7.

    Article  PubMed  CAS  Google Scholar 

  48. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest. 2009;136(6):1456–65.

    Article  PubMed  Google Scholar 

  49. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med. 2007;101(1):177–85.

    Article  PubMed  CAS  Google Scholar 

  50. Block JE, Stubbs H. Hip fracture-associated mortality reconsidered. Calcif Tissue Int. 1997;61(1):84.

    Article  PubMed  CAS  Google Scholar 

  51. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007;298(20):2389–98.

    Article  PubMed  CAS  Google Scholar 

  52. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65(12 Pt 2):S147–51.

    Article  PubMed  Google Scholar 

  53. Bolton CE, Stone MD, Edwards PH, Duckers JM, Evans WD, Shale DJ. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis. 2009;6(2):81–7.

    Article  PubMed  CAS  Google Scholar 

  54. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabet Care. 2004;27(10): 2478–84.

    Article  Google Scholar 

  55. Song Y, Klevak A, Manson JE, Buring JE, Liu S. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the women’s health study. Diabet Res Clin Pract. 2010;90(3): 365–71.

    Article  Google Scholar 

  56. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, et al. Insulin resistance and inflammation - a further systemic complication of COPD. COPD. 2007;4(2): 121–6.

    Article  PubMed  CAS  Google Scholar 

  57. Dennis RJ, Maldonado D, Rojas MX, Aschner P, Rondon M, Charry L, et al. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med. 2010;10:38.

    Article  PubMed  CAS  Google Scholar 

  58. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6.

    Article  PubMed  CAS  Google Scholar 

  59. Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax. 2001;56(6):432–7.

    Article  PubMed  CAS  Google Scholar 

  60. Sparrow D, Glynn RJ, Cohen M, Weiss ST. The relationship of the peripheral leukocyte count and cigarette smoking to pulmonary function among adult men. Chest. 1984;86(3):383–6.

    Article  PubMed  CAS  Google Scholar 

  61. van Eeden SF, Lawrence E, Sato Y, Kitagawa Y, Hogg JC. Neutrophils released from the bone marrow by granulocyte colony-stimulating factor sequester in lung microvessels but are slow to migrate. Eur Respir J. 2000;15(6):1079–86.

    Article  PubMed  Google Scholar 

  62. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agusti AG. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1664–8.

    PubMed  CAS  Google Scholar 

  63. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc. 2007;4(7):522–5.

    Article  PubMed  Google Scholar 

  64. de Jong JW, van der Belt-Gritter B, Koeter GH, Postma DS. Peripheral blood lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function. Respir Med. 1997;91(2):67–76.

    Article  PubMed  Google Scholar 

  65. Kim WD, Kim WS, Koh Y, Lee SD, Lim CM, Kim DS, et al. Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest. 2002;122(2):437–44.

    Article  PubMed  Google Scholar 

  66. Hodge SJ, Hodge GL, Reynolds PN, Scicchitano R, Holmes M. Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am J Physiol Lung Cell Mol Physiol. 2003;285(2):L492–9.

    PubMed  CAS  Google Scholar 

  67. Domagala-Kulawik J, Hoser G, Dabrowska M, Chazan R. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. Respir Med. 2007;101(6): 1338–43.

    Article  PubMed  Google Scholar 

  68. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–88.

    Article  PubMed  CAS  Google Scholar 

  69. Sauleda J, Garcia-Palmer FJ, Gonzalez G, Palou A, Agusti AG. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am J Respir Crit Care Med. 2000;161(1):32–5.

    PubMed  CAS  Google Scholar 

  70. Varadhachary AS, Salgame P. CD95 mediated T cell apoptosis and its relevance to immune deviation. Oncogene. 1998;17(25):3271–6.

    Article  PubMed  Google Scholar 

  71. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–8.

    Article  PubMed  CAS  Google Scholar 

  72. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol. 2000;190(5):619–26.

    Article  PubMed  Google Scholar 

  73. Traves SL, Smith SJ, Barnes PJ, Donnelly LE. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol. 2004;76(2):441–50.

    Article  PubMed  CAS  Google Scholar 

  74. Marques LJ, Teschler H, Guzman J, Costabel U. Smoker’s lung transplanted to a nonsmoker. Long-term detection of smoker’s macrophages. Am J Respir Crit Care Med. 1997;156(5):1700–2.

    PubMed  CAS  Google Scholar 

  75. Tomita K, Caramori G, Lim S, Ito K, Hanazawa T, Oates T, et al. Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med. 2002;166(5):724–31.

    Article  PubMed  Google Scholar 

  76. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2): 114–20.

    Article  PubMed  CAS  Google Scholar 

  77. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009;136(3):678–87.

    Article  PubMed  CAS  Google Scholar 

  78. Bon JM, Zhang Y, Duncan SR, Pilewski JM, Zaldonis D, Zeevi A, et al. Plasma inflammatory mediators associated with bone metabolism in COPD. COPD. 2010;7(3):186–91.

    Article  PubMed  Google Scholar 

  79. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1996;153(2):633–7.

    PubMed  Google Scholar 

  80. Dentener MA, Creutzberg EC, Pennings HJ, Rijkers GT, Mercken E, Wouters EF. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration. 2008;76(3):275–82.

    Article  PubMed  CAS  Google Scholar 

  81. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–34.

    Article  PubMed  CAS  Google Scholar 

  82. Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(1):234–8.

    Article  PubMed  CAS  Google Scholar 

  83. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, et al. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol. 2009;29(4):508–16.

    Article  PubMed  CAS  Google Scholar 

  84. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J. 1997;10(4):846–50.

    PubMed  CAS  Google Scholar 

  85. de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS, et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(6):1951–7.

    PubMed  Google Scholar 

  86. Wan YY, Flavell RA. Regulatory T cells, transforming growth factor-beta, and immune suppression. Proc Am Thorac Soc. 2007;4(3):271–6.

    Article  PubMed  CAS  Google Scholar 

  87. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(7):760–5.

    Article  PubMed  Google Scholar 

  88. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5(1):44–9.

    Article  PubMed  Google Scholar 

  89. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.

    Article  PubMed  CAS  Google Scholar 

  90. Powrie DJ, Wilkinson TM, Donaldson GC, Jones P, Scrine K, Viel K, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30(3):472–8.

    Article  PubMed  CAS  Google Scholar 

  91. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;18(4):CD003793.

    Google Scholar 

  92. Bolton CE, Broekhuizen R, Ionescu AA, Nixon LS, Wouters EF, Shale DJ, et al. Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD. Thorax. 2007;62(2):109–14.

    Article  PubMed  Google Scholar 

  93. Vogiatzis I, Stratakos G, Simoes DC, Terzis G, Georgiadou O, Roussos C, et al. Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax. 2007;62(11):950–6.

    Article  PubMed  Google Scholar 

  94. Sugawara K, Takahashi H, Kasai C, Kiyokawa N, Watanabe T, Fujii S, et al. Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD. Respir Med. 2010;104(12):1883–9.

    Article  PubMed  Google Scholar 

  95. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005;26(17):1765–73.

    Article  PubMed  CAS  Google Scholar 

  96. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–83.

    Article  PubMed  CAS  Google Scholar 

  97. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373–8.

    Article  PubMed  CAS  Google Scholar 

  98. Melbye H, Halvorsen DS, Hartz I, Medbo A, Brox J, Eggen AE, et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respir Med. 2007;101(12):2541–9.

    Article  PubMed  Google Scholar 

  99. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729–34.

    Article  PubMed  CAS  Google Scholar 

  100. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282–8.

    Article  PubMed  Google Scholar 

  101. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des. 2007;13(35): 3622–36.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Pulmonary, Critical Care, Sleep and Allergy Division, University of Nebraska Medical Center, Omaha, NE, USA

    Kristina L. Bailey, Jadvinder Goraya & Stephen L. Rennard

Authors
  1. Kristina L. Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jadvinder Goraya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen L. Rennard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristina L. Bailey .

Editor information

Editors and Affiliations

  1. Providence Veterans Affairs Medical Cent, Chief, Pulmonary and Critical Care, The Warren Alpert School of Medicine, Chalkstone Ave. 830, Providence, 02908, Rhode Island, USA

    Linda Nici

  2. St. Francis Hospital and Medical Center, Associate Chief, Pulmonary and Critical, University of Connecticut School of Medi, Woodland St. 114, Hartford, 06105, Connecticut, USA

    Richard ZuWallack

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bailey, K.L., Goraya, J., Rennard, S.L. (2012). The Role of Systemic Inflammation in COPD. In: Nici, L., ZuWallack, R. (eds) Chronic Obstructive Pulmonary Disease. Respiratory Medicine. Humana Press. https://doi.org/10.1007/978-1-60761-673-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-673-3_2

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-672-6

  • Online ISBN: 978-1-60761-673-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation